RxDoctor Payments Data

Peter Bernad

Neurology · Alexandria, VANPI 1336110477

Payments from drug & device makers

$56,378in general payments, 2019–2025

Across 859 payments — averaging $65.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$39K
  • Biogen$3K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Harmony Biosciences LLC$885
  • UCB, Inc.$876
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$2,20512%
  • Speaking & faculty fees$190%
  • Food & beverage$16,34686%
  • Education$3942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis80$38,744
Biogen47$2,791
AbbVie(2 entities)75$1,409
Teva Pharmaceuticals USA, Inc.49$1,127
Harmony Biosciences LLC51$885
UCB, Inc.33$876
Lilly USA, LLC40$850
Amneal Pharmaceuticals LLC37$784
Pfizer37$697
Vanda Pharmaceuticals Inc.30$666
Argenx US, Inc.26$480
Sunovion Pharmaceuticals Inc.24$434
Otsuka America Pharmaceutical, Inc.22$392
Neurocrine Biosciences, Inc.19$379
Avanir Pharmaceuticals, Inc.27$366
MDD US Operations, LLC5$339
Bristol Myers Squibb29$282
Neurelis, Inc.19$274
Livanova USA, Inc.8$266
SK Life Science, Inc.10$256
Axsome Therapeutics, Inc.8$243
Sumitomo Pharma America, Inc.13$219
Eisai Inc.11$214
Adamas Pharmaceuticals, Inc.12$209
Jazz Pharmaceuticals Inc.4$206
Upsher-smith Laboratories LLC10$205
Supernus Pharmaceuticals, Inc.10$200
AstraZeneca12$179
Genentech USA, Inc.7$176
Kyowa Kirin, Inc.8$154
Biohaven Pharmaceutical Holding Company Ltd.6$144
Sanofi7$136
Biohaven Pharmaceuticals, Inc.7$131
Corium, LLC6$121
Johnson & Johnson5$113
Banner Life Sciences, LLC5$108
Lundbeck LLC5$106
Takeda Pharmaceuticals U.S.A., Inc.4$105
Amgen4$101
Mallinckrodt Hospital Products Inc.5$89
Medtronic(2 entities)2$89
Acorda Therapeutics, Inc4$74
Nevro Corp.2$64
Catalyst Pharmaceuticals, Inc.3$58
Impel Pharmaceuticals Inc.3$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$53
Boston Scientific2$49
Promius Pharma LLC3$48
Avadel CNS Pharmaceuticals, LLC2$44
GE HealthCare2$44
Kedrion Biopharma, Inc.2$42
Tersera Therapeutics LLC2$41
EMD Serono, Inc.2$39
ANI Pharmaceuticals, Inc.2$38
Janssen Scientific Affairs, LLC1$34
Endo Pharmaceuticals Inc.1$23
Sandoz1$23
Insightec,inc1$23
Vertical Pharmaceuticals, LLC1$23
Idorsia Pharmaceuticals US Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,378 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$323,342
Medicare patients
313
Services billed
1,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate28$40,431
NuedextaDextromethorphan Hbr/Quinidine19$29,304
RytaryCarbidopa/Levodopa15$20,461
UbrelvyUbrogepant14$17,471
XcopriCenobamate14$16,932
Nurtec OdtRimegepant Sulfate12$16,792
AdlarityDonepezil Hcl12$6,874
Levetiracetam80$3,599
Lacosamide30$3,222
Lamotrigine68$2,185
Gabapentin108$1,688
Quetiapine Fumarate60$1,365
Modafinil23$1,325
Carbamazepine20$1,176
Levetiracetam ErLevetiracetam18$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$434$40,43128 claims
Avanir Pharmaceuticals, Inc.Nuedexta$366$29,30419 claims
Amneal Pharmaceuticals LLCRytary$784$20,46115 claims
AbbVieUbrelvy$1,409$17,47114 claims
SK Life Science, Inc.Xcopri$256$16,93214 claims
PfizerNurtec Odt$697$16,79212 claims
Corium, LLCAdlarity$121$6,87412 claims
Lilly USA, LLCOlanzapine$850$55920 claims
Upsher-smith Laboratories LLCTopiramate$205$27525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.

Other neurology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →